Article Text

Download PDFPDF

29 Dose modification for Chinese patients on niraparib maintenance treatment for platinum-sensitive recurrent ovarian cancer: A post hoc analysis
  1. Z Liu1,
  2. X Wu2,
  3. J Zhu3,
  4. R Yin4,
  5. J Yang5,
  6. J Liu6,
  7. J Wang7,
  8. L Wu8,
  9. T Tan9 and
  10. J Dong9
  1. 1The First Hospital of Jilin University, Department of Oncology, Changchun, China
  2. 2Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China
  3. 3Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Gynecologic Oncology, Hangzhou, China
  4. 4West China Second University Hospital, Sichuan University, 1.Department of Obstetrics and Gynecology 2. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China
  5. 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Gynecologic Oncology, Beijing, China
  6. 6Sun Yat-sen University Cancer Center , Department of Gynecologic Oncology, Guangzhou, China
  7. 7Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of Gynecologic Oncology, Changsha, China
  8. 8National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Gynecologic Oncology, Beijing, China
  9. 9Zai Lab (Shanghai) Co., Ltd, RandD Department, Shanghai, China


Introduction/Background*In the NOVA trial of niraparib maintenance treatment (MT) in platinum-sensitive recurrent ovarian cancer (PSROC), dose reduction due to treatment-emergent adverse events (TEAEs) occurred in 66.5% of patients initiating niraparib at 300 mg. Based on NOVA RADAR analysis, subsequent individualised starting dose (ISD) recommends patients with baseline bodyweight <77 kg or baseline platelet count <150×103/µl to initiate niraparib at 200 mg and all other patients, at 300 mg. ISD was adopted in NORA (NCT03705156), the published pivotal study in Chinese patients, who generally have lower body weights than Western patients. While niraparib demonstrated acceptable safety in NORA, dose reduction remained essential and occurred in 59.9% of patients. This post hoc analysis aims to characterise the major TEAEs necessitating dose modification in NORA, to inform TEAE management in Chinese patients receiving niraparib.

Methodology In NORA, adults with PSROC and complete/partial response to most recent platinum-containing chemotherapy were randomised 2:1 to niraparib or placebo MT of 28-day cycles. Primary endpoint was progression-free survival (PFS). First 16 patients started treatment at 300 mg, before ISD was implemented. Dose interruption ≤28 days and dose reduction were permitted. Niraparib-treated patients with stabilised dosing at Cycle 4 were analysed, with descriptive statistics summarising TEAEs and descriptive PFS analysis by dose levels at the beginning of Cycle 4.

Result(s)*During Month 1/2, platelet count decrease caused dose interruption and reduction in 32.8%/36.2% and 22.0%/23.6% of patients, respectively; neutrophil count decrease caused dose interruption and reduction in 9.0%/12.1% and 8.5%/9.2% of patients, respectively. These percentages decreased from Month 3 and remained low through Months 4–6 (figure 1). Anaemia-related dose interruption/reduction occurred in ≤10% of patients. Most patients’ stabilised doses at Cycle 4 were 100 mg (n=74) or 200 mg (n=78). These two groups had comparable baseline characteristics and showed similar PFS (figure 2) from Cycle 4 onward through 12 months, regardless of germline BRCA mutation status.

Abstract 29 Figure 1

Hematologic TEAEs Leading to niraparib dose interruption and reduction by month (Safety set)

Abstract 29 Figure 2

Kaplan-meier curves for progression free survival by niraparib dose level at the beginning of cycle 4 (Intention-to-treat Set)

Conclusion*Platelet count decrease and neutrophil count decrease were the major TEAEs necessitating niraparib dose modification. Early dose modification helped maintain safety and tolerability in Chinese patients receiving niraparib MT without compromising efficacy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.